This week in therapeutics




Licensing status

Publication and contact information


Prostate cancer

Kallikrein-related peptidase 4 (KLK4)

Cell culture and mouse studies suggest inhibition of KLK4 could help treat prostate cancer. In an androgen-sensitive prostate cancer cell line, small hairpin RNA-mediated knockdown of KLK4 decreased cell proliferation and increased apoptotic cell death compared with no knockdown. In mice, injection of Klk4-depleted prostate cancer cells resulted in slower tumor growth than injection of nondepleted cells. In a mouse xenograft model for prostate cancer, Klk4 small interfering RNA increased tumor regression compared with control siRNA. Next steps include optimization of siRNA delivery and generation of small molecule KLK4 inhibitors.

SciBX 6(29); doi:10.1038/scibx.2013.757
Published online Aug. 1, 2013

Unpatented; unavailable for licensing

Jin, Y. et al. Proc. Natl. Acad. Sci. USA; published online June 24, 2013;
Contact: Fahri Saatcioglu, University of Oslo, Oslo, Norway